Efficacy and Safety Results of INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo Controlled Study Evaluating Latozinemab (AL001) in FTD-GRN
ARTHUR MAYORGA1, Bradley Boeve2, Isabelle Le Ber3, Barbara Borroni4, Catherine Mummery5, Jonathan Rohrer6, Giovanna Zamboni7, Oezguer Onur8, James Rowe9, Adam Boxer10, Tina Schwabe1, Olga Kahn1, Julie Huang1, Ruchi Gupta1, Jinglin Zhong1, Caiyan Li1, Leonardo Guizzetti1, Lawrence Carter1, Tuan Nguyen1, Adam Simmons1, Tiffany Chow1, Balasubrahmanyam Budda1, Lovingly Park1, Sam Jackson1, Robert Paul1, Gary Romano1, Sara Kenkare-Mitra1, Arnon Rosenthal1, Giacomo Salvadore1
1Alector, Inc., 2Mayo Clinic, 3AP HP, 4University of Brescia, 5University College London Hospitals, 6Dementia Research Centre, 7University of Modena and Reggio Emilia, 8University Hospital Cologne, 9University of Cambridge, 10University of California, San Francisco
Objective:

INFRONT-3 is a randomized, double-blind, placebo-controlled phase 3 clinical trial evaluating latozinemab in frontotemporal dementia caused by heterozygous GRN mutations (FTD-GRN).

Background:

Latozinemab is a human recombinant monoclonal IgG1 antibody that binds to human sortilin receptors on the cell surface, thereby blocking the binding of progranulin (PGRN) to sortilin and reducing sortilin receptors on the cell surface via internalization. As a consequence, these actions result in reducing the degradation of PGRN and increasing PGRN levels. Latozinemab, therefore, counteracts the PGRN deficiency due to mutations in the progranulin gene (GRN), which are causal for development of FTD.

Design/Methods:

Eligible symptomatic participants aged 25–85 were known carriers of a heterozygous loss-of-function GRN mutation, with a global CDR® plus NACC FTLD (CDR-FTLD) score of 0.5 to 2 and a CDR-FTLD sum of boxes (SB) score >0.5, with a diagnosis of possible or probable bvFTD or PPA. Intravenous latozinemab 60 mg/kg or placebo was administered once monthly. Efficacy, safety, and biomarkers were assessed. Co-primary endpoints were change from baseline in CDR-FTLD-SB and change in plasma PGRN concentration over 96 weeks.

Results:

The primary 96-week analysis included 102 symptomatic participants. Latozinemab treatment increased plasma PGRN by 165% compared to placebo at week 96 (p-value <0.0001), confirming target engagement. Latozinemab did not show evidence of slowing disease progression versus placebo on the CDR-FTLD–SB. Secondary and exploratory endpoints—including fluid biomarkers (neurofilament light chain and glial fibrillary acidic protein) and volumetric MRI—showed no treatment-related effects on slowing disease progression. No adverse safety signals were identified.

Conclusions:

INFRONT-3 provides the first phase 3 efficacy and safety results for an investigational therapy in FTD-GRN. Sustained increase in plasma progranulin levels confirmed target engagement of latozinemab. However, no improvements were observed in clinical efficacy endpoints versus placebo, while no evidence of disease modification was found in the biomarker and imaging data.

10.1212/WNL.0000000000217902
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.